share_log

Avid Bioservices (NASDAQ:CDMO) Grows 8.7% This Week, Taking Five-year Gains to 67%

Avid Bioservices (NASDAQ:CDMO) Grows 8.7% This Week, Taking Five-year Gains to 67%

本周Avid Bioservices (纳斯达克代码:CDMO)上涨8.7%,五年收益率达67%。
Simply Wall St ·  08/20 07:33

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Avid Bioservices, Inc. (NASDAQ:CDMO) share price is up 67% in the last five years, that's less than the market return. Unfortunately the share price is down 5.3% in the last year.

当你买入并持有股票长期投资时,你肯定希望它能提供正面回报。此外,你通常希望看到股价上涨速度比市场快。不幸的是,对于股东来说,虽然Avid Bioservices, Inc.(纳斯达克:CDMO)股价在过去五年中上涨了67%,但这比市场回报低。更不幸的是,股价在过去一年中下跌了5.3%。

Since the stock has added US$58m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

由于该股票上周市值增加了5800万美元,所以让我们看看潜在业绩是否推动了长期回报。

Avid Bioservices isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Avid Bioservices目前没有盈利,因此大多数分析师会关注营收增长,以了解该基础业务增长的速度。不盈利公司的股东通常希望有强劲的营收增长。那是因为快速的营收增长可以轻松推断出相当大的利润预测。过去五年,Avid Bioservices的营收每年以21%的速度增长。这远高于大多数未盈利的公司。虽然股东获得了利润,但该期间的11%增幅与整体市场相比并不令人印象深刻。你可以说市场仍然非常怀疑,考虑到营收的增长。股票可能过去被定价过高,但如果你正在寻找被低估的增长股,这些数字表明这里可能存在机会。

For the last half decade, Avid Bioservices can boast revenue growth at a rate of 21% per year. That's well above most pre-profit companies. It's nice to see shareholders have made a profit, but the gain of 11% over the period isn't that impressive compared to the overall market. You could argue the market is still pretty skeptical, given the growing revenues. It could be that the stock was previously over-priced - but if you're looking for underappreciated growth stocks, these numbers indicate that there might be an opportunity here.

虽然较广泛的市场在去年上涨了约28%,但Avid Bioservices的股东亏损了5.3%。即使是好股票的股价有时也会下跌,但是在对一个公司进行太多投资之前,我们想要看到业务基本指标的提高。好消息是,长期股东有赚钱,五年来年增长率为11%。可能最近的抛售是一个机会,因此可能值得检查基础数据是否存在长期的增长趋势。虽然考虑市场情况可能对股价产生不同的影响,但还有其他更重要的因素。例如,承担风险 - Avid Bioservices有2个警告标志,我们认为你需要知道。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以看到以下收益和营收的变化情况(通过单击图像了解精确值)。

big
NasdaqCM:CDMO Earnings and Revenue Growth August 20th 2024
NasdaqCM:CDMO的收益和营业收入增长2024年8月20日

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Avid Bioservices stock, you should check out this free report showing analyst profit forecasts.

我们喜欢近十二个月内内部人士已购买股票的情况。话虽如此,大多数人认为收益和营收增长趋势是业务更重要的指导。如果你正在考虑买或卖Avid Bioservices的股票,你应该查看这个免费报告,其中显示了分析师的利润预测。

A Different Perspective

不同的观点

While the broader market gained around 28% in the last year, Avid Bioservices shareholders lost 5.3%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 11% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Avid Bioservices has 2 warning signs we think you should be aware of.

即使较广泛的市场在去年上涨了约28%,Avid Bioservices的股东仍然亏损了5.3%。即使是好股票的股价有时也会下跌,但在对一个公司进行太多投资之前,我们想要看到业务基本指标的提高。好消息是,长期股东有赚钱,五年来年增长率为11%。可能最近的抛售是一个机会,因此可能值得检查基础数据是否存在长期的增长趋势。尽管考虑市场情况可能对股价产生不同的影响,但还有其他更重要的因素。例如,承担风险 - Avid Bioservices有2个警告标志,我们认为你需要知道。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).

如果您喜欢与管理层共同购买股票,那么您可能会喜欢这个免费的公司列表(提示:大多数公司没有受到关注)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发